The results showed that ginsenoside Rh4 could effectively increase the expression of FXR in mice with NAFLD, induce the increase in SHP, and thus downregulate the expression of CYP7A1 protein in the liver. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.